|
1) Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409: 307-12
|
|
|
|
2) Patel L, Buckels A, Kinghorn I, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003; 300: 472-6
|
|
|
|
|
|
3) Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun. 2001; 285: 561-4
|
|
|
|
|
|
4) Savage D, Sewter C, Klenk E, et al. Resistin / Fizz3 expression in relation to obesity and per-oxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001; 50: 2199-202
|
|
|
|
|
|
5) Steppan C, Lazar M. The current biology of resistin. J Intern Med. 2004; 255: 439-47
|
|
|
|
|
|
6) Patel S, Rajala M, Rossetti L, et al. Disulfide-dependent multimeric assembly of resistin family hormones. Science. 2004; 304: 1154-8
|
|
|
|
|
|
7) Gerber M, Boettner A, Seidel B, et al. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Metab. 2005; 90: 4503-9
|
|
|
|
|
|
8) Pravenec M, Kazdova L, Landa V, et al. Trans-genic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem. 2003; 278: 45209-15
|
|
|
|
|
|
9) Rangwala S, Rich A, Rhoades B, et al. Abnormal glucose homeostasis due to chronic hyperresist-inemia. Diabetes. 2004; 53: 1937-1941
|
|
|
|
|
|
10) Banerjee R, Rangwala S, Shapiro J, et al. Regulation of fasted blood glucose by resistin. Science. 2004; 303: 1195-8
|
|
|
|
|
|
11) Steppan CM, Wang J, Whiteman EL, et al. Activation of SOCS-3 by resistin. Mol Cell Biol. 2005: 25: 1569-75
|
|
|
|
|
|
12) Kaser S, Kaser A, Sandhofer A, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003: 309: 286-90
|
|
|
|
|
|
13) Nagaev I, Bokarewa M, Tarkowski A, et al. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leuko-cytes and adipocytes. PLoS One. 2006; 1: e31
|
|
|
|
|
|
14) Lehrke M, Reilly MP, Millington SC, et al. An inflammatory cascade leading to hyperresist-inemia in humans. PLoS Med. 2004; 1: e45
|
|
|
|
|
|
15) Qatanani M, Szwergold NR, Greaves DR, et al. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resist-ance in mice. J Clin Invest. 2009 Feb 2 [Epub head of print]
|
|
|
|
|
|
16) Osawa H, Yamada K, Onuma H, et al. The G/G genotype of a resistin single-nucleotide polymor-phism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004; 75: 678-86
|
|
|
|
|
|
17) Osawa H, Onuma H, Ochi M, et al. Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun. 2005; 335: 596-602
|
|
|
|
|
|
18) Osawa H, Tabara Y, Kawamoto R, et al. Plasma resistin, associated with single nucleotide polymorphism-420, is correlated with insulin resistance, lower HDL, and high sensitivity CRP in the Japanese general population. Diabetes Care. 2007; 30: 1501-6
|
|
|
|
|
|
19) Cho Y, Youn B, Chung S, et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin con-centrations in humans. Diabetologia. 2004; 47: 559-65
|
|
|
|
|
|
20) Ohmori R, Momiyama Y, Kato R, et al. Asso-ciations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol. 2005; 46: 379-80
|
|
|
|
|
|
21) Engert JC, Vohl MC, Williams SM, et al. 5' flanking variants of resistin are associated with obesity. Diabetes. 2002; 51: 1629-34
|
|
|
|
|
|
22) Kunnari A, Ukkola O, Kesaniemi YA. Resistin polymorphisms are associated with cerebro-vascular disease in Finnish Type 2 diabetic patients. Diabet Med. 2005; 22: 583-9
|
|
|
|
|
|
23) Norata GD, Ongari M, Garlaschelli K, et al. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med. 2007; 262: 104-12
|
|
|
|
|
|
24) Tokuyama Y, Osawa H, Ishizuka T, et al. Serum resistin level is associated with insulin sensitivity in Japanese type 2 diabetes. Metabolism. 2007; 56: 693-8
|
|
|
|
|
|
25) Jung HS, Youn BS, Cho YM, et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism. 2005; 54: 314-20
|
|
|
|
|
|
26) Kamin D, Hadigan C, Lehrke M, et al. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab. 2005; 90: 3423-6
|
|
|
|
|
|
27) Ochi M, Osawa H, Hirota Y, et al. Frequency of the G/G genotype of resistin single nucleotide polymorphism at -420 appears to be increased in younger-onset type 2 diabetes. Diabetes. 2007; 56: 2834-8
|
|
|
|
|
|
28) Xu JY, Sham PC, Xu A, et al. Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study. Clin Endocrinol(Oxf). 2007; 66: 211-7
|
|
|
|
|
|
29) Hivert MF, Manning AK, McAteer JB, et al. Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes. 2009; 58: 750-6
|
|
|
|
|
|
30) Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005; 111: 932-9
|
|
|
|
|
|
31) Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardio-vascular disease in patients with end-stage renal disease. Clin Endocrinol(Oxf). 2005; 62: 242-9
|
|
|
|
|
|
32) Shin HJ, Park S, Yoon SJ, et al. Association between serum resistin and carotid intima media thickness in hypertension patients. Int J Cardiol. 2008; 125: 79-84
|
|
|
|
|
|
33) Osawa H, Ochi M, Tabara Y, et al. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol(Oxf). 2008; 69: 74-80
|
|
|
|
|
|
34) Takata Y, Osawa H, Kurata M, et al. Hyper-resistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension. 2008; 51: 534-9
|
|
|
|
|
|
35) Norata GD, Ongari M, Garlaschelli K, et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007; 156: 279-84
|
|
|
|
|
|
36) Burnett MS, Devaney JM, Adenika RJ, et al. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab. 2006; 91: 64-8
|
|
|
|
|
|
37) Lubos E, Messow CM, Schnabel R, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis. 2007; 193: 121-8
|
|
|
|
|
|
38) Tsukahara T, Nakashima E, Watarai A, et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2009; 84: 179-86
|
|
|
|
|
|
39) Efstathiou SP, Tsiakou AG, Tsioulos DI, et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta. 2007; 378: 78-85
|
|
|
|
|
|
40) Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol. 2009; 29: 1144-9
|
|
|
|
|
|
41) Frankel DS, Vasan RS, D'Agostino RB, Sr, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol. 2009; 53: 754-62
|
|
|
|
|
|
42) Axelsson J, Bergsten A, Qureshi AR, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtra-tion rate and inflammation, but not with insulin resistance. Kidney Int. 2006; 69: 596-604
|
|
|
|
|